TrialBMC cancer2022

A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).

Emmanuel Deshayes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.